Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

Item

http://www.wikidata.org/entity/Q35731438

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

@ast

Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

@en

type

Item

label

Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

@ast

Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

@en

prefLabel

Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

@ast

Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

@en

P1476

Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

@en

P2093

Chien-Wen Tseng

http://www.w3.org/2001/XMLSchema#string

Grace A Lin

http://www.w3.org/2001/XMLSchema#string

Jinoos Yazdany

http://www.w3.org/2001/XMLSchema#string

R Adams Dudley

http://www.w3.org/2001/XMLSchema#string

Randi Chen

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Medicare formulary coverage for top-selling biologics

Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries.

Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials.

Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.

P304

1474-1480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.39079

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25900105

http://www.w3.org/2001/XMLSchema#string

P932

4464809

http://www.w3.org/2001/XMLSchema#string